• Full Prescribing Information, including BOXED WARNING
  • Medication Guide
  • Patient Site
  • Medical Information
  • References

    References:
    1. INFLECTRA [prescribing information]. Incheon, Republic of Korea: Celltrion, Inc.; 2021.
    2. The Weinberg Group. FDA approves INFLECTRA™, the second US biosimilar. https://weinberggroup.com/fda-news/fda-approves-inflectra-the-second-us-biosimilar/. Published April 7, 2016. Accessed July 31, 2019.
    3. Celltrion. CT-P13 (infliximab biosimilar). Briefing document for the US FDA Arthritis Advisory Committee. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM484860.pdf. Published February 9, 2016. Accessed July 31, 2019.
    4. Ryan AM. Frontiers in nonclinical drug development: biosimilars. Vet Pathol. 2015;52(2):419-426.
    5. Food and Drug Administration (FDA). Biologics Website. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm. Accessed July 31, 2019.
    6. European Medicines Agency, European Commission. Biosimilars in the EU. Information guide for healthcare professionals. 2017. www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500226648. April 27, 2017. Accessed July 31, 2019.
    7. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19:411-419.
    8. Data on file. Pfizer Inc., New York, NY.
    9. US Food and Drug Administration. FDA briefing document. Arthritis Advisory Committee meeting. BLA 125544: CT-P13, a proposed biosimilar to Remicade® (infliximab), Celltrion. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM484860.pdf. Published February 9, 2016. Accessed July 31, 2019.
    10. US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to Reference Product. Guidance for Industry. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf. Published April 2015. Accessed July 31, 2019.
    11. Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393:1699-1707.
    12. Data on file. Pfizer Inc., New York, NY.
    13. Stanley K. Design of randomized controlled trial. Circulation. 2007;115:1164-1169.
    14. Hannan EL. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC: Cardiovascular Interventions. 2008;1(3):211-217.
    15. Kovesdy CP, Kalantar-Zadeh K. Observational studies vs randomized controlled trials: avenues to causal inference in nephrology. Adv Chronic Kidney Dis. 2012;19(1):1-13. doi: 10.1053/j.ackd.2011.09.004.
    16. Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions, the ISPOR real-world data task force report. Value in Health. 2007;10(5): 326-335.
    17. Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS, et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763-1774.
    18. Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295-304.
    19. Ho SL, Niu F, Pola S, Velayos FS, Ning X, Hui RL. Effectiveness of switching from reference product Infliximab to Infliximab-Dyyb in patients with inflammatory bowel disease in an integrated healthcare system in the United States: A retrospective, propensity score-matched, non-inferiority cohort study. BioDrugshttps://doi.org/ 10.1007/ s40259-020-00409-y. Published February 2020.
    20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
    21. Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13* compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority. www.thelancet.com. 2017;389(10086):2304-2316.
    22. Faccin F, Tebbey P, Alexander E, Wang X, Cui L, Albuquerque T. The design of clinical trials to support the switching and alternation of biosimilars. Expert Opin Biol Ther. 2016;16(12):1445-1453.

    The brand names included throughout are the properties of their respective owners.

    About

    • Basics of Biologics and Biosimilars
    • About INFLECTRA
    • References

    INFLECTRA Data

    Evaluated in both infliximab-naive & patients stable on Remicade®.2

    Learn more

    ** This is an optional area where footnotes can live.

    INDICATIONS

    INFLECTRA® is indicated for:

    Crohn's Disease

    • Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy
    • Reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD
      ​​​​​​​

    ​​​​​​​Pediatric Crohn's Disease

    • Reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age or older with moderately to severely active CD who have had an inadequate response to conventional therapy
      ​​​​​​​

    Ulcerative Colitis

    • Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy

    Pediatric Ulcerative Colitis

    • Reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy
      ​​​​​​​

    Rheumatoid Arthritis

    • Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate (MTX)

    Ankylosing Spondylitis

    • Reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS)
      ​​​​​​​

    Psoriatic Arthritis

    • Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA)

    Plaque Psoriasis

    • The treatment of adult patients with chronic severe (ie, extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate
    • ​​​​​​​INFLECTRA® should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician

    SERIOUS INFECTIONS

    ​​​​​​​Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue INFLECTRA® (infliximab-dyyb) if a patient develops a serious infection or sepsis.

    Reported infections include:

    • Active tuberculosis (TB), including reactivation of latent TB. Patients frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before and during treatment with INFLECTRA®. Treatment for latent infection should be initiated prior to treatment with INFLECTRA®.
    • ​​​​​​​Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients may present with disseminated, rather than localized, disease. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
    • Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

    ​​​​​​​​​​​The risks and benefits of treatment with INFLECTRA® should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with INFLECTRA®, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.​​​​​​​

    ​​​​​​​Risk of infection may be higher in patients greater than 65 years of age, pediatric patients, patients with comorbid conditions and/or patients taking concomitant immunosuppressant therapy. In clinical trials, other serious infections observed in patients treated with infliximab included pneumonia, cellulitis, abscess, and skin ulceration.

    MALIGNANCIES

    Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including infliximab products. Approximately half of these cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months after the first dose of therapy. Most of the patients were receiving concomitant immunosuppressants.

    Postmarketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including infliximab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported cases have occurred in patients with Crohn's disease or ulcerative colitis and most were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. Carefully assess the risks and benefits of treatment with INFLECTRA®, especially in these patient types.

    In clinical trials of all TNF blockers, more cases of lymphoma were observed compared with controls and the expected rate in the general population. However, patients with Crohn’s disease, rheumatoid arthritis, or plaque psoriasis may be at higher risk for developing lymphoma. In clinical trials of some TNF blockers, including infliximab products, more cases of other malignancies were observed compared with controls. The rate of these malignancies among infliximab-treated patients was similar to that expected in the general population whereas the rate in control patients was lower than expected. Cases of acute and chronic leukemia have been reported with postmarketing TNF blocker use. As the potential role of TNF blocker therapy in the development of malignancies is not known, caution should be exercised when considering treatment of patients with a current or a past history of malignancy or other risk factors such as chronic obstructive pulmonary disease (COPD).

    Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy, including infliximab products. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.

    A population-based retrospective cohort study found a 2- to 3-fold increase in the incidence of invasive cervical cancer in women with rheumatoid arthritis treated with infliximab compared to biologics-naïve patients or the general population, particularly those over 60 years of age. A causal relationship between infliximab products and cervical cancer cannot be excluded. Periodic screening should continue in women treated with INFLECTRA®.

    CONTRAINDICATIONS

    The use of INFLECTRA® at doses >5 mg/kg is contraindicated in patients with moderate or severe heart failure. INFLECTRA® is contraindicated in patients with a previous severe hypersensitivity reaction to infliximab or any of the inactive ingredients of INFLECTRA® or any murine proteins (severe hypersensitivity reactions have included anaphylaxis, hypotension, and serum sickness).

    HEPATITIS B REACTIVATION

    TNF blockers, including infliximab products, have been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases were fatal. Patients should be tested for HBV infection before initiating INFLECTRA®. For patients who test positive, consult a physician with expertise in the treatment of hepatitis B. Exercise caution when prescribing INFLECTRA® for patients identified as carriers of HBV, and monitor closely for active HBV infection during and following termination of therapy with INFLECTRA®. Discontinue INFLECTRA® in patients who develop HBV reactivation, and initiate antiviral therapy with appropriate supportive treatment. Exercise caution when considering resumption of INFLECTRA®, and monitor patients closely.

    HEPATOTOXICITY

    Severe hepatic reactions, including acute liver failure, jaundice, hepatitis, and cholestasis have been reported in patients receiving infliximab products postmarketing. Some cases were fatal or required liver transplant. Aminotransferase elevations were not noted prior to discovery of liver injury in many cases. Patients with symptoms or signs of liver dysfunction should be evaluated for evidence of liver injury. If jaundice and/or marked liver enzyme elevations (eg, ≥5 times the upper limit of normal) develop, INFLECTRA® should be discontinued, and a thorough investigation of the abnormality should be undertaken.

    HEART FAILURE

    In a randomized, placebo-controlled study in patients with moderate or severe heart failure (NYHA Functional Class III/IV), higher mortality rates and a higher risk of hospitalization were observed at Week 28 at a dose of 10 mg/kg, and higher rates of cardiovascular events were observed at both 5 mg/kg and 10 mg/kg. There have been postmarketing reports of new onset and worsening heart failure, with and without identifiable precipitating factors. Patients with moderate or severe heart failure taking INFLECTRA® (≤5 mg/kg) or patients with mild heart failure should be closely monitored, and treatment should be discontinued if new or worsening symptoms appear.

    HEMATOLOGIC EVENTS

    Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal) have been reported. The causal relationship to infliximab-product therapy remains unclear. Exercise caution in patients who have ongoing or a history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs and symptoms of blood dyscrasias or infection. Consider discontinuation of INFLECTRA® in patients who develop significant hematologic abnormalities.

    HYPERSENSITIVITY 

    Infliximab products have been associated with hypersensitivity reactions that differ in their time of onset. Anaphylaxis, acute urticaria, dyspnea, and hypotension have occurred in association with infusions of infliximab products. Medications for the treatment of hypersensitivity reactions should be available. 

    CARDIOVASCULAR AND CEREBROVASCULAR REACTIONS DURING AND AFTER INFUSION​​​​​​​

    Serious cerebrovascular accidents, myocardial ischemia/infarction (some fatal), hypotension, hypertension, and arrhythmias have been reported during and within 24 hours of initiation of infliximab product infusion. Cases of transient visual loss have been reported during or within 2 hours of infliximab product infusion. Monitor patients during infusion, and if a serious reaction occurs, discontinue infusion. Manage reactions according to signs and symptoms.

    NEUROLOGIC EVENTS 

    Agents that inhibit TNF have been associated with CNS manifestation of systemic vasculitis, seizure, and new onset or exacerbation of CNS demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barré syndrome. Exercise caution when considering INFLECTRA® in patients with these disorders and consider discontinuation if these disorders develop.​​​​​​​

    CONCURRENT ADMINISTRATION WITH OTHER BIOLOGICS

    Concurrent use of infliximab products with anakinra, abatacept, tocilizumab, or other biologics used to treat the same conditions as INFLECTRA® is not recommended because of the possibility of an increased risk of infection. Care should be taken when switching from one biologic to another, since overlapping biological activity may further increase the risk of infection.

    AUTOIMMUNITY 

    Treatment with infliximab products may result in the formation of autoantibodies and in the development of a lupus-like syndrome. Discontinue INFLECTRA® treatment if symptoms of a lupus-like syndrome develop.​​​​​​​

    VACCINATIONS AND USE OF LIVE VACCINES/THERAPEUTIC INFECTIOUS AGENTS

    Prior to initiating INFLECTRA®, update vaccinations in accordance with current vaccination guidelines. Live vaccines or therapeutic infectious agents should not be given with INFLECTRA® due to the possibility of clinical infections, including disseminated infections.

    At least a 6-month waiting period following birth is recommended before the administration of any live vaccine to infants exposed in utero to INFLECTRA®.

    ADVERSE REACTIONS

    In clinical trials with infliximab products, the most common adverse reactions occurring in >10% of infliximab treated patients included infections (eg, upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain.​​​​​​​ 

    For more information, please see accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.​​​​​​​

      INFLECTRA® is indicated for:

      Crohn's Disease

      • Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy
      • Reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD

      Pediatric Crohn's Disease

      • Reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age or older with moderately to severely active CD who have had an inadequate response to conventional therapy

      ​​​​​​​​​​​​​​​​​​​​​Ulcerative Colitis 

      • Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy​​​​​​​​​​​​​​

      ​​​​​​​​​​​​​​​​​​​​​Pediatric Ulcerative Colitis 

      • Reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy​​​​​​​

      ​​​​​​​Rheumatoid Arthritis

      • Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate (MTX)​​​​​​​​​​​​​​

      ​​​​​​​Ankylosing Spondylitis

      • Reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS)​​​​​​​

      ​​​​​​​Psoriatic Arthritis

      • Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA)​​​​​​​

      ​​​​​​​Plaque Psoriasis

      • The treatment of adult patients with chronic severe (ie, extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate
      • INFLECTRA® should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician​​​​​​

      ​​​​​​​​​​Please see full Prescribing Information, including BOXED WARNING and Medication Guide, for INFLECTRA®.

      The brand names included throughout are the properties of their respective owners.